

**Ohio Department of Medicaid (ODM)
Drug Utilization Review (DUR) Board
Quarterly Meeting
May 17th, 2016**

The quarterly meeting of the ODM DUR Board was called to order at 12:02 PM EST in room 1952 on the 19th Floor of the Riffe Center, 77 S. High Street, Columbus, Ohio. Lenard Presutti, DO, presided. The following Board members were present:

David Brookover, R.Ph.
Michael K. Farrell, M.D.
Thomas E. Gretter, M.D.
Robert B. Kubasak, R.Ph.
Lenard G. Presutti, D.O., Chair

Also present from ODM were: Michael Howcroft, R.Ph., Margaret Scott, R.Ph., DUR Administrator. Pam Heaton, R.Ph., Ph.D. represented the University of Cincinnati. Robyn Satterfield, PharmD, Jill RK Griffith, PharmD, and Benjamin Link, PharmD were in attendance from Goid Health Systems (GHS). Approximately 15 observers were present, most representatives from pharmaceutical manufacturers.

Reading, Correction, & Approval of Previous Minutes:

The February 16th, 2016, DUR Board minutes were approved (1st D. Brookover, 2nd R. Kubasak).

DUR Committee Report:

There were no new announcements related to the DUR Committee Report.

Health Plan Policy:

M. Scott updated the Board on the activities related to the change in PBM vendor from Xerox to GHS. M. Scott also updated the Board in regards to the Healthy Ohio Program, which was identified as being available for public comment on the Medicaid website. Plans were also discussed regarding moving foster children and participants in the Ohio Department of Health's Bureau for Children with Medical Handicaps (BCMh) program into the Managed Care population. M. Scott also identified that changes were being undertaken to the Medicaid spenddown program that should enhance continuity of care.

Unfinished Business:

Conflict of Interest Policy

All members of the DUR Board have signed the conflict of interest policy for calendar year 2016.

Prospective DUR Criteria

GHS clinical account manager R. Satterfield presented a report on quantity per day limits for Board consideration. It was identified that the limits were developed based upon the current quantity limits, a

review of other Medicaid states and through 3 meetings with the DUR Committee. Discussion ensued regarding the appropriateness of opioid limits in reference to other opioid policies. It was identified that the long-term goal would be to use morphine equivalent dose (MED) limits in addition to quantity limits to ensure beneficiary safety. The Board moved to accept the limits (1st R. Kubasak, 2nd M. Farrell) with a review of the limits to take place at a future meeting (November).

New Business:

Opioids

The ODM DUR Administrator M. Scott led a discussion regarding strategic measures for Ohio Medicaid recipients in regards to opioid medications. M. Scott reviewed the current refill thresholds as identified in the Ohio Administrative Code (OAC) and identified areas where the Managed Care Plans (MCPs) of Ohio had come together to pursue consistent opioid edits across all MCPs. The proposed edits include an early refill threshold of 90%, a limit of concurrent short-acting narcotics to 3 prescriptions in a 30 day timeframe, a limit of concurrent long-acting narcotics to 3 prescriptions in a 30 day timeframe, and a limit to the number of prescribers to 3 per 30 days. M. Scott shared data prepared by P. Heaton of the University of Cincinnati which identified that this would potentially impact 2% of current beneficiaries. D. Brookover moved that the Board accept the proposal that these edits be placed in the Ohio Medicaid Fee-for-Service population which was accepted by the Board.

High-Risk Combinations

The ODM DUR Administrator M. Scott led a discussion regarding high-risk combinations of medications. M. Scott identified that this was based upon work by the Ohio Bureau of Workers' Compensation. M. Scott shared data prepared by P. Heaton of the University of Cincinnati which identified drug combinations of two or three agents and the frequency with which those combinations occur. A discussion ensued regarding the risk posed by the combination of anti-anxiety (benzodiazepine) and/or narcotics and/or sedative hypnotics with reference to the recently published CDC Opioid Guidelines and the statistics from the Department of Health. M. Scott requested that the Board approve profile reviews for patients with two to three drug combinations of combination of anti-anxiety (benzodiazepine) and/or narcotics and/or sedative hypnotics. A discussion ensued regarding the appropriate timing and information to include in letters to physicians and/or pharmacists. The Board accepted the proposal.

Announcements:

The Board indicated that the next meeting will take place on Tuesday, September 20th in the ODM Office in the Lazarus Building.

Adjournment:

Dr. Presutti adjourned the meeting at 12:30 PM EST.